Integrated drug discovery contract research organization (CRO) Sygnature Discovery has invested £3.75 million in an Azenta compound management storage system that can also provide customer libraries.
In the midst of International Gaucher Disease Awareness Month, GlobalData has highlighted a 'critical' issue within the Gaucher disease landscape: the significant lack of neuronopathic therapies.
Advanced tech company, PhaseV, has raised $15 million in funding that it says it will use to ‘push the boundaries of machine learning for clinical trial optimization’.
Clinical stage pharma company PharmaKure believe their combined drug targeting amyloid deposits associated with Alzheimer’s Disease can bring quality of life to patients.
Feedback has been submitted to the US Food and Drug Administration (FDA) with guidelines intended for sponsors of clinical trials related to psychedelic compounds.
A collaboration has been formed between the US pharmacy chain Walgreens and the Cardiovascular Research Foundation (CRF) to measure how prevalent valvular heart disease (VHD) is among older Americans.
Physics-powered GenAI Biotech, Gero, announced yesterday (October 18) that it had closed a $6 million series A extension round with funding from Melnicheck Investments and other investors.
The Gen AI revolution promises to redefine various industries, with the life sciences sector at the forefront of this transformation. OSP had the chance to speak to Tarun Mathur, CEO at Indegene, who was keen to allay many of the fears those in the industry...
Saama, a provider of artificial intelligence (AI) based solutions, announced today (October 17) that it has formed a multi-year agreement with biopharma giant, AstraZeneca.
The heavy burden on immediate family members with neurodegenerative diseases and their caregivers, was the initial driving force to study pharmacy for Andrea Pfeifer.
Complete clinical trials solution company, Hawthorne Effect, announced today (October 10) it had successfully recruited more than 1,000 patients in 48 states plus Hawaii for a study to qualify the prevalence of valvular heart disease (VHD).
A new patient-first service that will support sponsors and sites accelerate the development of their therapies has been launched by Innovative Trials yesterday (October 9).
Contract research organization (CRO), Phastar, has had its net-zero target approved by SBTi which it hopes to achieve by adopting stringent sustainability standards.
Calliditas Therapeutics AB announced on Friday (October 5) that the European Medicines Agency (EMA) has issued a positive opinion on the company’s drug, setanaxib in Alport Syndrome (AS).
Former UK Prime Minister, David Cameron, will lead the international efforts of The Oxford-Harrington Rare Disease Centre's new initiative, the therapeutics accelerator.
Veradigm Inc. and Holmusk have announced the next step in their strategic collaboration helping them move closer to their vision of creating a single source of truth for behavioral health.
A study to evaluate the effect of seladelparm, a small molecule treatment by CymaBay Therapeutics, Inc. on patients with cirrhosis was announced this month (September 21).
Drug discovery will benefit from a virtual artificial intelligence (AI) expert thanks to Opportunity Pharma and OpenEye, Cadence Molecular Sciences joining forces.
Exscientia plc will receive an upfront cash payment of $20 million from Merck KGaA, Darmstadt, Germany, as the companies collaborate plus potential payments of up to $674 million in aggregate.
A study of MedRhythm’s MR-001 neurorehabilitation system, designed to improve walking and ambulation in adults with chronic stroke impairment, will use Curavit Clinical Research as its virtual contract research organization (VCRO).
OSP spoke to Vesta Marciulioniene, director global regulatory clinical services at ICON Biotech, a contract research organisation who shares insights on the new EMA guideline for computerised systems and electronic data in clinical trials and what new...
CymaBay announced recently the initiation of its 52-week, placebo-controlled, randomized, phase 3 study — 'Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase (ALP) Levels in subjects with Primary Biliary Cholangitis...
Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning...
Eight new companies have joined The BioInnovation Institute’s (BII’s) Venture Lab acceleration program for early-stage companies, it was announced today (August 31).
With more than 63 biopharma companies attending and 15 event partners sharing solutions, the 7th Annual IPF Summit being held in Boston next month (September 2023) is not to be missed.
Emerald Cloud Lab (ECL) was the world’s first highly automated cloud laboratory, was set up by two friends, Brian Frezza and D.J Kleinbaum who grew up together and joined forces after their PhDs to found the company.
FORE Biotherapeutics yesterday (August 23) announced the closing of its $75 million (£59 million) series D financing, led by the SR One and co-led by Medicxi and joined by existing investors.
A partnership between Banner Health and nference will offer more ‘potent insight generation, offering researchers the option to examine more inclusive data’.
QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.
Healthcare technology company Koneska is extending its contribution to critical neuroscience research by collaborating with an academic partnership program.
A partnership between technology company Fluree and Vitality TechNet is a ‘groundbreaking effort’ to shorten timelines within the drug discovery process.
Nathan Johnson has 20 years’ experience in clinical research as an innovator and programmer with expertise in statistical analysis and reporting, SAS programming, standards development, and data management.
OSP was fortunate enough to have an interesting discussion with Stephen Corson, who is a statistics manager at Phastar, a specialist biometrics CRO headquartered in the UK.
At-risk families of patients diagnosed with motor neurone disease (MND), better known in the US as amyotrophic lateral sclerosis (ALS) will now have access to genetic sequencing thanks to a financial award from Innovate UK.
Uncensored and brutally honest accounts from participants, caregivers and health professionals providing insights into clinical trial experiences are being shared by The Portrait Project.
A company that ‘translates science into survival’ by developing new therapies has completed its acquisition of a technology company leading in artificial intelligence (AI) and machine learning (ML).
The US Food and Drug Administration (FDA) has today (July 31) given clearance via its 510(k) process to one of the artificial intelligence solutions cleared for colonoscopy.